Cytox has developed an in vitro diagnostic test to identify genetic markers for the diagnosis of early stage Alzheimer’s Disease (AD), supported by leading academics in the field from Oxford, Birmingham, Cardiff and UCL and incorporating data sets from several European research groups.

The development of new AD drugs has been hampered by the lack of an effective early diagnostic test, resulting in the cost of recruiting patients for clinical trials being prohibitively high. The availability of a prognostic genetic test with high predictive accuracy will cut the costs of AD drug discovery by allowing pharmaceutical companies to stratify patient groups for clinical trials and enable early lifestyle interventions for high risk groups. Cytox is planning to commercialise its variaTECT™/SNPfitR™ genetic test globally via third party genotyping laboratories, creating a major opportunity for the pharma industry to improve outcomes for people affected by this devastating condition.

Visit website